EUVIMEDEUVIMED entdecken
Open Access

Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes

Mustapha Abubakar iD, Máire A Duggan, Shaoqi Fan iD, Ruth M Pfeiffer iD, Scott Lawrence, Karun Mutreja, Alyssa Klein, Hela Koka, Thomas U Ahearn, Jill E Henry, Brian L Sprague, Pamela M Vacek und 10 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Mustapha Abubakar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health (NIH), Bethesda, MD, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Stromal Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Breast Cancer Research Foundation, NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aggressive (typically high-grade) breast cancers (BCs) remain major contributors to BC-related mortality globally. The tissue changes underpinning their etiology and outcomes, however, remain poorly characterized.

Methods

Spatially resolved machine-learning algorithms were used to characterize “stromal disruption” as a morphological metric of reduced/altered extracellular matrix and increased immune, inflammatory, and/or wound response-related processes in normal, benign breast disease (BBD), and invasive hematoxylin and eosin (H&E)-stained breast tissues. Associations of stromal disruption with BC etiologic factors were assessed among 4023 healthy breast tissue donors, its impact on BC incidence was assessed among 974 BBD patients in a nested case–control study, while its prognostic associations were assessed in 4 BC patient cohorts (n = 4223).

Results

Epidemiologic risk factors for aggressive BC, including younger age, multiparity, Black race, obesity, and family history, demonstrated strong associations with increasing stromal disruption in H&E sections prior to tumor development. Substantial stromal disruption in BBD H&E was associated with ∼4-fold increased risk of aggressive (high-grade) BC and ∼3 years shorter latency from BBD to BC diagnosis, independently of BBD histology. Across BC cohorts, stromal disruption in H&E was associated with aggressive (mostly high-grade) tumor phenotypes and with markedly poor prognosis among ER-positive patients, irrespective of histology. The immunobiology of stromal disruption reflected heightened innate (CD68+), adaptive (CD3+CD4+, CD3+CD8+), immunoregulatory (CD3+CD4+FOXP3+), immune escape (PD1+PDL1+), endothelial (CD31+), and myofibroblast (α-SMA+) marker expression.

Conclusion

Our findings highlight the active stromal role in aggressive BC etiology and outcomes, opening possibilities for readily identifying high-risk women across the BC continuum that may benefit from stroma-centric preventative or therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsStromal CellsHumansFemaleMiddle AgedCase-Control StudiesRisk FactorsPrognosisAdultAgedMachine LearningBreastBiomarkers, TumorTumor Microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health (NIH), Bethesda, MD, United States.
  • Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Molecular and Digital Pathology Laboratory, Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
  • Biospecimen Collection and Banking Core, Susan G. Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
  • University of Vermont College of Medicine and Vermont Cancer Center, Burlington, VT, United States.
  • Kaiser Permanente Center for Health Research, Portland, OR, United States.

ORCID-Profile: Mustapha Abubakar, Shaoqi Fan, Ruth M Pfeiffer, Nicolas Titiloye, Jonine D Figueroa, Montserrat Garcia-Closas, Gretchen L Gierach

Förderung

  • Breast Cancer Research Foundation
  • NCI NIH HHS
  • NIH
  • NCI
  • Division of Cancer Epidemiology and Genetics
  • National Cancer Institute

Zitieren

APA

Abubakar, M., Duggan, M. A., Fan, S., Pfeiffer, R. M., Lawrence, S., Mutreja, K., Klein, A., Koka, H., Ahearn, T. U., Henry, J. E., Sprague, B. L., Vacek, P. M., Weaver, D. L., Richert-Boe, K., Kimes, T. M., Titiloye, N., Edusei, L., Figueroa, J. D., Yang, X. R., …, & Gierach, G. L. (2025). Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf070

Vancouver

Abubakar M, Duggan MA, Fan S, Pfeiffer RM, Lawrence S, Mutreja K, et al. Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf070

BibTeX
@article{Abubakar2025,
  author = {Abubakar, Mustapha and Duggan, Máire A and Fan, Shaoqi and Pfeiffer, Ruth M and Lawrence, Scott and Mutreja, Karun and Klein, Alyssa and Koka, Hela and Ahearn, Thomas U and Henry, Jill E and Sprague, Brian L and Vacek, Pamela M and Weaver, Donald L and Richert-Boe, Kathryn and Kimes, Teresa M and Titiloye, Nicolas and Edusei, Lawrence and Figueroa, Jonine D and Yang, Xiaohong R and Garcia-Closas, Montserrat and Rohan, Thomas E and Gierach, Gretchen L},
  title = {Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf070}
}
Kostenlos starten →